Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that a
positive judgment has been given by the UK High Court in support of
Teva's case against AstraZeneca relating to the validity of EP 1,085,877
covering the SMART ( S ingle inhaler M aintenance A nd R eliever
T herapy) indication for AstraZeneca's fixed dose
formoterol/budesonide combination product, Symbicort ® .
for Teva Announces UK High Court Gives Positive Judgment in the Company’s Patent Case Against AstraZeneca investment picks